Amgen, Inc. (AMGN) Misses Q4 EPS by 1c; Guides FY12 EPS
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Price: $439.33 +1.29%
Financial Fact:
Total operating expenses: 3.28B
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Total operating expenses: 3.28B
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Amgen, Inc. (NASDAQ: AMGN) reported Q4 EPS of $1.21, $0.01 worse than the analyst estimate of $1.22. Revenue for the quarter came in at $3.97 billion versus the consensus estimate of $3.91 billion.
Amgen, Inc. sees FY2012 EPS of $5.90-$6.15, versus the consensus of $5.94.
For earnings history and earnings-related data on Amgen, Inc. (AMGN) click here.
Amgen, Inc. sees FY2012 EPS of $5.90-$6.15, versus the consensus of $5.94.
For earnings history and earnings-related data on Amgen, Inc. (AMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FTC files amicus brief challenging Amgen's Enbrel patent acquisition
- Amgen (AMGN) PT Raised to $400 at Cantor Fitzgerald on Higher Sales Estimates
- Vireo Growth completes acquisition of C21 Investments
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
